A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
Medical science has long been on the hunt for a deeper understanding of the devastating scarring of the body's organs known ...
Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback